Weak D Testing is not Required for D- Patients With C-E- Phenotype
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Although testing to detect weak D antigens using the antihuman globulin reagent is not required for D- patients in many countries, it is routinely performed in Korea. However, weak D testing can be omitted in D- patients with a C-E- phenotype as this indicates complete deletion of the RHD gene, except in rare cases. We designed a new algorithm for weak D testing, which consisted of RhCE phenotyping followed by weak D testing in C+ or E+ samples, and compared it with the current algorithm with respect to time and cost-effectiveness. Methods: In this retrospective study, 74,889 test results from January to July 2017 in a tertiary hospital in Korea were analyzed. Agreement between the current and proposed algorithms was evaluated, and total number of tests, time required for testing, and test costs were compared. With both algorithms, RHD genotyping was conducted for samples that were C+ or E+ and negative for weak D testing. Results: The algorithms showed perfect agreement (agreement=100%; κ=1.00). By applying the proposed algorithm, 29.56% (115/389 tests/yr) of tests could be omitted, time required for testing could be reduced by 36% (8,672/24,084 min/yr), and the test cost could be reduced by 16.53% (536.11/3,241.08 USD/yr). Conclusions: Our algorithm omitting weak D testing in D- patients with C-E- phenotype may be a cost-effective testing strategy in Korea.
Abstract
Background: Although testing to detect weak D antigens using the antihuman globulin reagent is not required for D- patients in many countries, it is routinely performed in Korea. However, weak D testing can be omitted in D- patients with a C-E- phenotype as this indicates complete deletion of the RHD gene, except in rare cases. We designed a new algorithm for weak D testing, which consisted of RhCE phenotyping followed by weak D testing in C+ or E+ samples, and compared it with the current algorithm with respect to time and cost-effectiveness. Methods: In this retrospective study, 74,889 test results from January to July 2017 in a tertiary hospital in Korea were analyzed. Agreement between the current and proposed algorithms was evaluated, and total number of tests, time required for testing, and test costs were compared. With both algorithms, RHD genotyping was conducted for samples that were C+ or E+ and negative for weak D testing. Results: The algorithms showed perfect agreement (agreement=100%; κ=1.00). By applying the proposed algorithm, 29.56% (115/389 tests/yr) of tests could be omitted, time required for testing could be reduced by 36% (8,672/24,084 min/yr), and the test cost could be reduced by 16.53% (536.11/3,241.08 USD/yr). Conclusions: Our algorithm omitting weak D testing in D- patients with C-E- phenotype may be a cost-effective testing strategy in Korea.
참고문헌 (20)
- Sandler SG, "It’s time to phase in RHD genotyping for patients with a serologic weak D phenotype. College of American Pathologists Transfusion Medicine Resource Committee Work Group", Transfusion, 55, pp.680~689 (2015)
- Daniels G, "Variants of RhD--current testing and clinical consequences", Br J Haematol, 161, pp.461~470 (2013)
- Jenkins CM, "Incidence of weak D in blood donors typed as D positive by the Olympus PK 7200", Immunohematology, 21, pp.152~154 (2005)
- Sandler SG, "Policies and procedures related to testing for weak D phenotypes and administration of Rh immune globulin: results and recommendations related to supplemental questions in the Comprehensive Transfusion Medicine survey of the College of American Pathologists", Arch Pathol Lab Med, 138, pp.620~625 (2014)
- AABB, "Standards for Blood Banks and Transfusion services. 18th ed", American Association of Blood Banks, 327~328 (2016)
- Han KS, "Transfusion medicine", pp.367~370 (2014), Korea Medical Book Publishing Company
- Japan Society of Transfusion Medicine and Cell Therapy, "Transfusion examination technology training course committee Ver.1.3.1. Inspection manual for blood transfusion", Japan Society of Transfusion Medicine and Cell Therapy, Transfusion examination technology training course committee, 3~5 (2017)
- Hors collection, "Transfusion medicine: the French model", pp.61~82 (2013), John Libbey Eurotext
- Kim JY, "Molecular characterization of D- Korean persons: development of a diagnostic strategy", Transfusion, 45, pp.345~352 (2005)
- "2018 Checklist for Excellent Laboratory Certification_Transfusion Medicine" (2017)[URL]
- Shao CP, "Transfusion of RhD-positive blood in “Asia type” DEL recipients", N Engl J Med, 362, pp.472~473 (2010)
- Seo MH, "An effective diagnostic strategy for accurate detection of RhD variants including Asian DEL type in apparently RhD-negative blood donors in Korea", Vox Sang, 111, pp.425~430 (2016)
- 임영애, "혈액원 대상 ABO 및 D 혈액형 외부 숙련도 조사사업 보고(2015)", 대한수혈학회지, 27(1), pp.68~78 (2016), 대한수혈학회[DOI]
- Korean Medical Association, "Health insurance review and assessment service of Korea", pp.110~ (2017), Kyungsung Media
- Landis JR, "The measurement of observer agreement for categorical data", Biometrics, 33, pp.159~174 (1977)
- Sandler SG, "Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the RHD genotype", Br J Haematol, 179, pp.10~19 (2017)
- Pham BN, "Anti-D investigations in individuals expressing weak D Type 1 or weak D Type 2: allo- or autoantibodies?", Transfusion, 51, pp.2679~2685 (2011)
- Flegel WA, "Six years’ experience performing RHD genotyping to confirm D- red blood cell units in Germany for preventing anti-D immunizations", Transfusion, 49, pp.465~471 (2009)
- Ogasawara K, "Molecular basis for D- Japanese: identification of novel DEL and D- alleles", Vox Sang, 109, pp.359~365 (2015)
- Wang M, "Anti-D alloimmunisation in pregnant women with DEL phenotype in China", Transfus Med, 25, pp.163~169 (2015)